about
MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphomaFatal tracheal aspergillosis during rituximab combined chemotherapy for diffuse large B-cell lymphoma that developed after lung transplantation.Clinicopathological features of primary splenic follicular lymphoma.Prognostic factors for histiocytic and dendritic cell neoplasms.A distinct subtype of Epstein Barr virus positive T/NK-cell lymphoproliferative disorder: Adult patients with chronic active Epstein Barr virus infection-like features.Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy.Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.Expression pattern of immunosurveillance-related antigen in adult T-cell leukemia/lymphoma.Peripheral T-cell lymphoma, not otherwise specified: a retrospective single-center analysis.The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma.PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negativeAnaplastic large cell lymphoma, with 1,25(OH)D-mediated hypercalcemia: A case reportExpression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patientsA case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatmentGemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 RearrangementsMethotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors[Clinical features of adult-onset chronic active Epstein-Barr virus infection]
P50
Q37142412-5B8128DA-43B6-43BC-9507-6F36DAAAAD36Q41000625-9BA5DC81-4FB2-4B1F-9EC5-C714FF0F6D43Q41925009-8843F434-84A0-412B-AE0F-ED4E0103637EQ47094254-8040FCEC-4C92-45CB-B492-0E762744BACEQ47565503-FB58AE23-5CED-481E-978C-1FB6195BCF52Q48157671-A7DF8699-5DA3-4433-809A-8A0DB1761143Q48303194-1B348D8B-D6ED-40D9-8A75-899910D85FD7Q49344056-F8A726E0-3FF4-4456-870E-3E24C9DA6C8AQ50202911-41B2972B-56AD-45A1-8739-D7E295C904FEQ50237174-8DBED812-2065-4F5A-9F55-C5C083923927Q51640313-A3D6E51F-7707-4EB6-A945-26306F474512Q58610326-CEC62DB7-A881-496C-A736-3D0D4F9F7752Q64270249-9F25F77A-DAD9-493A-8D06-A4BE895670D9Q88227428-7C12E52C-28A1-41F5-A538-2EFDCCAC9722Q90255204-BC7EA304-409E-49AF-A35C-0CF0B98069DBQ91415724-0F83A166-0E83-4206-9748-774B3FDEF7C6Q92215933-7CA67144-4113-4E71-BD52-2D55643B1FF6Q93106031-72347263-59F2-423A-9D5A-D4AF8C8947AD
P50
description
researcher ORCID ID = 0000-0002-9040-285X
@en
wetenschapper
@nl
name
Keisuke Kawamoto
@ast
Keisuke Kawamoto
@en
Keisuke Kawamoto
@es
Keisuke Kawamoto
@nl
type
label
Keisuke Kawamoto
@ast
Keisuke Kawamoto
@en
Keisuke Kawamoto
@es
Keisuke Kawamoto
@nl
prefLabel
Keisuke Kawamoto
@ast
Keisuke Kawamoto
@en
Keisuke Kawamoto
@es
Keisuke Kawamoto
@nl
P31
P496
0000-0002-9040-285X